Comparison of treatment effects between 4.9% N-acetyl-aspartyl glutamic acid and 0.05% cyclosporine A eye drops in dry eye patients

Shin, Daeun Chloe; Min, Jisang

doi:10.1007/s00417-022-05682-x

Cited by 3 publications

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To determine the appropriate sample size for this study, we utilized PASS 15.0 software for power analysis. The calculation was based on changes observed in OSDI scores among dry eye patients treated with 0.05% cyclosporine eye drops in a previous study by Shin D and Sang Min J [ 16 ]. In this reference study, the baseline OSDI score was 25.30 ± 19.04, which significantly decreased to 13.63 ± 14.94 after three months of treatment ( P < 0.001).…”

Section: Methodsmentioning

confidence: 99%

Efficacy of topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in post-refractive surgery chronic dry eye patients with ocular pain

Zhao,

Chen,

Duan

et al. 2024

BMC Ophthalmol

View full text Add to dashboard Cite

Background The management of post-refractive surgery dry eye disease (DED) can be challenging in clinical practice, and patients usually show an incomplete response to traditional artificial tears, especially when it is complicated with ocular pain. Therefore, we aim to investigate the efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate treatment in post-refractive surgery DED patients with ocular pain unresponsive to traditional artificial tears. Methods We enrolled 30 patients with post-refractive surgery DED with ocular pain who were unresponsive to traditional artificial tears. Topical 0.05% cyclosporine A and 0.1% sodium hyaluronate were used for 3 months. They were evaluated at baseline and 1 and 3 months for dry eye and ocular pain symptoms and objective parameters, including Numerical Rating Scale (NRS), Neuropathic Pain Symptom Inventory modified for the Eye (NPSI-Eye), tear break-up time (TBUT), Schirmer I test (SIt), corneal fluorescein staining (CFS), corneal sensitivity, and corneal nerve morphology. In addition, tear levels of inflammatory cytokines and neuropeptides were measured using the Luminex assay. Results After 3 months of treatment, patients showed a statistically significant improvement in the ocular surface disease index (OSDI), TBUT, SIt, CFS, and corneal sensitivity (all P < 0.01) using linear mixed models. As for ocular pain parameters, the NRS and NPSI-Eye scores were significantly reduced (both P < 0.05) and positively correlated with the OSDI and CFS scores. Additionally, tear IL-1β, IL-6, and TNF-α levels were improved better than pre-treatment (P = 0.01, 0.03, 0.02, respectively). Conclusion In patients with post-refractive surgery DED with ocular pain, combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate treatment improved tear film stability, dry eye discomfort, and ocular pain, effectively controlling ocular inflammation. Trial registration Registration number: NCT06043908.

show abstract

Section: Methodsmentioning

confidence: 99%

Efficacy of topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in post-refractive surgery chronic dry eye patients with ocular pain

Zhao,

Chen,

Duan

et al. 2024

BMC Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Dysregulated para-inflammation can be corrected by means of the prolonged use of artificial tears containing minimal doses of safe steroids or other molecules in order to re-equilibrate ocular surface homeostasis. Although to date there are no published efficacy data, agents acting on the complement system like N-Acetylaspartylglutamic acid [ 35 ] or membrane stabilizers such as cromolyn [ 36 ] may be effective in reducing the secretion of a wide range of inflammatory mediators, including cytokines such as IL-1β, IL-6, IL-8 and IFN-γ and chemokines such as CXCL10, CCL2, CCL3 and CCL4, whose levels are typically high in DED [ 37 ]. Other tear substitutes can control excessive evaporation by adding polar lipids to the tear film lipid layer [ 38 ].…”

Section: Principles Of Treatmentmentioning

confidence: 99%

Dealing with the Persistent Pathogenic Issues of Dry Eye Disease: The Importance of External and Internal Stimuli and Tissue Responses

Rolando¹,

Barabino

Giannaccare

et al. 2023

JCM

View full text Add to dashboard Cite

The immune system plays a central role in protecting the ocular surface from exogenous and endogenous insults, maintaining tissue homeostasis thanks to the mechanism of para-inflammation. This physiological adaptive response may induce resident macrophages/monocytes to produce cytokines and growth factors in order to promote epithelial cell recovery. In case of well-controlled para-inflammation, caused by a low amount of stress, cell viability and function are maintained. When stress becomes too intense, there is a response characterized by the activation of autophagic pathways and consequent cell death. Dysregulated homeostasis and chronic sub-clinical inflammation are the starting points for the development of a stable, chronic inflammatory disease, which leads to ocular surface damage, and, in turn, to the onset or progression of chronic dry eye disease (DED). The long-term management of DED should consider all of the pathogenic issues involved in the disease, including the control of persistent external or internal stresses that are capable of activating and maintaining the para-inflammatory adaptive mechanisms, potentially leading to full-blown inflammation. Dysregulated para-inflammation can be corrected by means of the prolonged use of tear substitutes containing minimal doses of safe corticosteroids or other anti-inflammatory molecules (e.g., corticosteroid, cyclosporine) in order to re-equilibrate ocular surface homeostasis.

show abstract

Successful management of dry eye disease with a new eye drop formulation combining hyaluronic acid, trehalose, and N-acetyl-aspartyl-glutamic acid (NAAGA)

El Fekih,

Khairallah,

Ben Amor

et al. 2024

Journal Français d'Ophtalmologie

View full text Add to dashboard Cite

Comparison of treatment effects between 4.9% N-acetyl-aspartyl glutamic acid and 0.05% cyclosporine A eye drops in dry eye patients

Cited by 3 publications

References 24 publications

Efficacy of topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in post-refractive surgery chronic dry eye patients with ocular pain

Efficacy of topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in post-refractive surgery chronic dry eye patients with ocular pain

Dealing with the Persistent Pathogenic Issues of Dry Eye Disease: The Importance of External and Internal Stimuli and Tissue Responses

Successful management of dry eye disease with a new eye drop formulation combining hyaluronic acid, trehalose, and N-acetyl-aspartyl-glutamic acid (NAAGA)

Contact Info

Product

Resources

About